# Suzhou Huayi Lejian Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/suzhou-huayi-lejian-biotechnology-co

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Latest round: Series A (Mar 2, 2022)
- Investors on record: 7

## About

Established in 2019 and based in Suzhou, China, Suzhou Huayi Lejian Biotechnology Co., Ltd. is a biotechnology company that focuses on biopharmaceutical. In February 2018, the company raised an undisclosed amount in strategy investment from Tencent Investment, Skycus Capital, Guangkong Dongtai Investment Management and Gaorong Capital. The company also established a research and development center in Beijing.

The company has developed an efficient vector platform and its products which can be used in the field of hemophilia A and has entered the clinical trial stage. The company has also launched an AAV gene therapy platform, whose products are in clinical trials. The company also built a cGMP production base is a chain of new drug development and production experimental platform with plasmid and virus development, production and quality control functions.

The company will promote the manufacturing, registration, clinical and research of the company's lead gene therapy products, as well as accelerate the development of the company's products in other targeted liver and targeted neuro areas.

## Funding rounds

- Series A, Mar 2, 2022 — Hong Shan, China Everbright, China Renaissance, Sunshine Insurance Group, Tsing Song Capital, Beijing Life Science Park Innovation Investment Fund, Hainan Fructus Yingfu Investment

## Investors

- Hong Shan — Series A
- China Everbright (https://capitalatlas.ai/funds/china-everbright) — Series A
- China Renaissance (https://capitalatlas.ai/funds/china-renaissance) — Series A
- Sunshine Insurance Group — Series A
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series A
- Beijing Life Science Park Innovation Investment Fund — Series A
- Hainan Fructus Yingfu Investment — Series A